Roche arthritis drug effective as sole therapy
Zurich, May 26, 2011
Roche's rheumatoid arthritis drug RoActemra helps treat patients with the painful and debilitating disease regardless of whether it is given on its own or in combination with another drug, a late-stage study showed.
The news could boost Roche's bid to bolster its position beyond oncology where it is market leader.
Currently, RoActemra, which is known as Actemra outside of Europe, can be prescribed in combination with older drug methotrexate, or MTX, to treat adults with moderate to severe rheumatoid arthritis who respond inadequately to other treatments.
Roche said in a statement up to 40 percent of the patients given older drug MTX which is widely used to treat RA, either did not adequately respond to it or experienced side-effects and needed other drugs to control their inflammation.
"We carry peak sales for RoActemra of 2 billion Swiss francs. The drug is currently approved as second line treatment. Should Roche get approval for first line biologic treatment, we could see a doubling of the peak sales," Vontobel analyst Andrew Weiss said.
Rheumatoid arthritis is a chronic, progressive inflammatory disease of the joints and surrounding tissues that is associated with intense pain, irreversible joint destruction and systemic complications such as fatigue and anaemia.
Actemra is the first approved treatment for rheumatoid arthritis that works by blocking receptors to another protein called interleukin-6.
The data from the study, which involved 566 patients with inadequate response to MTX, will be presented at this year's European League Against Rheumatism congress, Roche said. -Reuters
More Health & Environment Stories
- SARS virus claims one more victim in Saudi
- New support group comes to overeaters' rescue
- RAK Hospital launches urinary clinic for women
- NBAD backs Emiratis on Antarctica trip
- Cut sugar intake drastically urges WHO
- Al khaliji to fund Qatar recycling plant
- Qatar researcher in 360km breast cancer run
- New facilitator to open in DHCC
- Many countries lack capacity to prevent hearing loss
- QUIT NOW: Passive smoking hurts kids' arteries
- San Francisco to ban plastic water bottles
- GSK wins home toothpaste award for Sensodyne
- E-integration vital to GCC healthcare industry
- Fakih IVF unveils two new genetic tests
- 2 die from H1N1 in Oman
- Al Noor Hospitals targets domestic growth
- Medical panel on the way in Bahrain
- 40pc of UAE adults ‘have hypertension’
- Saudi diabetics urged to stay away from camels
- GCC readies plan to fight heart diseases
- Bahrain opens sickle cell hospital
- Hazardous waste focus for Oman summit
- Infectious viruses to be tracked by satellite in UAE
- Mafraq Hospital names new surgery chief
- Saudi health ministry seals BMJ partnership
- Need for medical simulation training highlighted
- UAE-France discuss healthcare collaboration
- Seha focus on patient centred services
- Saudi-Tokyo firms in wastewater technology JV
- Leading experts at Dubai diabetes conference